SANGAMO THERAPEUTICS, INC Contracts & Agreements

License Agreement between the Company and Genentech, Inc., dated August 2, 202 (Filed With SEC on November 12, 2024)

Form of Pre-Funded Warrant to Purchase Common Stock (Filed With SEC on March 25, 2024)

Form of Warrant to Purchase Common Stock (Filed With SEC on March 25, 2024)

Form of Securities Purchase Agreement, dated March 21, 2024 by and among Sangamo Therapeutics, Inc. and the purchasers party thereto (Filed With SEC on March 25, 2024)

Placement Agent Agreement, dated March 21, 2024 by and among Sangamo Therapeutics, Inc. and Barclays Capital Inc. and Cantor Fitzgerald & Co (Filed With SEC on March 25, 2024)

Description of Capital Stock (Filed With SEC on March 13, 2024)

Amended and Restated 2018 Equity Incentive Plan of Sangamo Therapeutics, Inc (Filed With SEC on May 25, 2022)

Letter Agreement between the Company and David Mark McClung dated November 1, 2021 (Filed With SEC on February 24, 2022)

Amended and Restated Office and Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated October 18, 2021 (Filed With SEC on February 24, 2022)

Letter Agreement between the Company and (Filed With SEC on November 4, 2021)

Letter Agreement between the Company and (Filed With SEC on August 5, 2021)

Ninth Amendment to Triple Net Laboratory Lease (Filed With SEC on May 4, 2021)

Letter Agreement between the Company and (Filed With SEC on May 4, 2021)

Description of (Filed With SEC on February 24, 2021)

Letter Agreement dated as of January 22, 2021 between Sangamo Therapeutics, Inc. and Sung Lee (Filed With SEC on January 28, 2021)

Amendment No. 2 to Research Collaboration and License Agreement between the Company and Pfizer Inc., dated July 21, 2020 (Filed With SEC on November 4, 2020)

Collaboration and License (Filed With SEC on November 4, 2020)

Open Market Sale Agreement, dated August 5, 2020, between Sangamo Therapeutics, Inc. and Jefferies LLC (Filed With SEC on August 5, 2020)

Employment Agreement between the Company and Mark McClung effective as of April 13, 2020 (Filed With SEC on August 5, 2020)

Letter Agreement (Filed With SEC on August 5, 2020)

Seventh Amendment to the Triple Net Laboratory Lease Agreement, dated May 2 (Filed With SEC on August 5, 2020)

Eighth Amendment to the Triple Net Laboratory Lease Agreement, dated May 29, 2020, between the Registrant and Point Richmond R&D Associates II, LLC (Filed With SEC on August 5, 2020)

Amended and Restated 2018 Equity Incentive Plan of Sangamo Therapeutics, Inc (Filed With SEC on May 22, 2020)

Collaboration and License Agreement among the Company, Biogen MA, Inc. and Biogen International GmbH, dated February 26, 2020 (Filed With SEC on May 11, 2020)

Stock Purchase Agreement between the Company and Biogen MA, Inc., dated February 26, 2020 (Filed With SEC on May 11, 2020)

Form of Indemnity Agreement (Filed With SEC on May 11, 2020)

Description of Securities of the Company (Filed With SEC on February 28, 2020)

Employment Agreement between the Company and Sung Lee effective as of October 31, 2019 (Filed With SEC on February 28, 2020)

Employment Agreement between the Company and Gary Loeb effective as of June 6, 2019 (Filed With SEC on February 28, 2020)

Employment Agreement between the Company and Rolf Andrew (Andy) Ramelmeier effective as of November 1, 2017 (Filed With SEC on February 28, 2020)

Letter Amendment, dated December 17, 2019, to the Collaboration and License Agreement between the Company and Pfizer Inc., dated May 10, 2017 (Filed With SEC on February 28, 2020)

Amended and Restated Collaboration and License Agreement between the Company and Kite Pharma, Inc., dated as of September 11, 2019 (Filed With SEC on November 6, 2019)

Amendment No. 1 to Research Collaboration and License Agreement between the Company and Pfizer., dated December 27, 2017, dated as of March 21, 2019 (Filed With SEC on May 8, 2019)

Underwriting Agreement, dated April 4, 2019, by and between Sangamo Therapeutics, Inc. and Cowen and Company, LLC, Wells Fargo Securities, LLC and Barclays Capital Inc., as... (Filed With SEC on April 4, 2019)

2018 Equity Incentive Plan French Stock-Options Sub-Plan (the French Options Sub-Plan) (Filed With SEC on March 1, 2019)

2018 Equity Incentive Plan French Restricted Stock Unit Award Sub-Plan (the French RSU Sub-Plan) (Filed With SEC on March 1, 2019)

Form of Stock Option Grant Notice (French employees) under the 2018 Plan and the French Options Sub-Plan (Filed With SEC on March 1, 2019)

Form of Stock Option Agreement (French Employees) under the 2018 Plan and the French Options Sub-Plan (Filed With SEC on March 1, 2019)

Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (French employees) under the 2018 Plan and the French RSU Sub-Plan (Filed With SEC on March 1, 2019)

Amended and Restated Severance Plan (Filed With SEC on March 1, 2019)

Employment Agreement between the Company and Heather D. Turner, effective February 12, 2018 (Filed With SEC on March 1, 2019)

Employment Agreement between the Company and Stphane Boissel, effective October 1, 2018 (Filed With SEC on March 1, 2019)

Employment Agreement between the Company and Adrian Woolfson, effective January 21 2019 (Filed With SEC on March 1, 2019)

Fourth Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated June 10, 2016 (Filed With SEC on March 1, 2019)

Fifth Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&D Associates II, LLC, dated July 10, 2017 (Filed With SEC on March 1, 2019)

First Amendment to Lease Agreement between the Company and Marina Boulevard Property, LLC dated January 1, 2019 (Filed With SEC on March 1, 2019)

Amendment Agreement to the Share Purchase Agreement dated October 1, 2018, among the Company and the Sellers (Filed With SEC on November 6, 2018)

Amendment No. 1 to the Tender Offer Agreement dated October 1, 2018, between the Company and TxCell (Filed With SEC on November 6, 2018)

Sixth Amendment to the Triple Net Laboratory Lease Agreement, dated May 23, 2018, between the Registrant and Point Richmond R&D Associates II, LLC (Filed With SEC on August 8, 2018)

Share Purchase Agreement dated July 20, 2018, among the Company and the Sellers (Filed With SEC on July 23, 2018)

Tender Offer Agreement dated July 20, 2018, between the Company and TxCell (Filed With SEC on July 23, 2018)

Collaboration and License Agreement between the Company and Kite Pharma, Inc., dated February 20, 2018 (Filed With SEC on May 10, 2018)

Amended and Restated Incentive Compensation Plan (Filed With SEC on May 10, 2018)

Underwriting Agreement, dated April 25, 2018, by and between Sangamo Therapeutics, Inc. and Merrill Lynch Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities LLC and Cowen... (Filed With SEC on April 26, 2018)

Form of Restricted Stock Unit Award Agreement under the 2013 Plan (Filed With SEC on March 1, 2018)

Offer Letter between the Company and Curt A. Herberts, dated August 16, 2010 (Filed With SEC on March 1, 2018)

Separation Agreement between the Company and Dale Ando, dated February 21, 2017 (Filed With SEC on March 1, 2018)

Lease Agreement between the Company and Marina Boulevard Property, LLC dated November 3, 2017 (Filed With SEC on March 1, 2018)

Research Collaboration and License Agreement between the Company and Pfizer Inc., dated December 28, 2017 (Filed With SEC on March 1, 2018)

Collaboration and License Agreement between Sangamo Therapeutics, Inc. and Pfizer, Inc., dated May 10, 2017 (Filed With SEC on August 9, 2017)

10,000,000 Shares SANGAMO THERAPEUTICS, INC. Common Stock, $0.01 par value UNDERWRITING AGREEMENT (Filed With SEC on June 21, 2017)

SANGAMO THERAPEUTICS, INC. AMENDED AND RESTATED AT-THE-MARKET OFFERING PROGRAM SALES AGREEMENT (Filed With SEC on May 26, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on May 10, 2017)

AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on May 10, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on May 10, 2017)

SANGAMO THERAPEUTICS, INC. EXECUTIVE SEVERANCE PLAN INTRODUCTION (Filed With SEC on May 10, 2017)

Signature(s) Guaranteed:Medallion Guarantee Stamp (Filed With SEC on January 6, 2017)

SANGAMO BIOSCIENCES, INC. AT-THE-MARKET OFFERING PROGRAM SALES AGREEMENT (Filed With SEC on December 7, 2016)

EIGHTH AMENDMENT TO THE RESEARCH AND COMMERCIAL LICENSE OPTION AGREEMENT (Filed With SEC on October 27, 2016)

First Amendment to the License Agreement (Filed With SEC on October 27, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on August 4, 2016)

Exhibit A (Filed With SEC on May 5, 2016)

Exhibit A 2016 BT Development Plan [***] (Filed With SEC on February 18, 2016)

AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT Between SANGAMO BIOSCIENCES, INC. And SHIRE INTERNATIONAL GMBH *** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH... (Filed With SEC on October 30, 2015)

sEVENTH AMENDMENT TO THE LICENSE AGREEMENT (Filed With SEC on August 6, 2015)

INDEMNIFICATION AGREEMENT (Filed With SEC on August 6, 2015)

SANGAMO BIOSCIENCES, INC. AMENDED AND RESTATED 2013 STOCK INCENTIVE PLAN article One GENERAL PROVISIONS (Filed With SEC on June 25, 2015)

RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between Sangamo BioSciences, Inc. and Juvenile Diabetes Research Foundation International Table of Contents (Filed With SEC on April 28, 2015)

GLOBAL RESEARCH, DEVELOPMENT AND COMMERCIALIZATION COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 7, 2014)

Amendment of 2013 Stock Incentive Plan on Reduction of Share Reserve (Filed With SEC on May 7, 2014)

NINTH AMENDMENT (Filed With SEC on May 7, 2014)

SANGAMO BIOSCIENCES, INC. 4,444,444 Shares of Common Stock par value $0.01 UnderwritingAgreement (Filed With SEC on March 25, 2014)

SECOND AMENDMENT TO LEASE (Filed With SEC on November 4, 2013)

THIRD AMENDMENT TO LEASE (Filed With SEC on November 4, 2013)

AGREEMENTAND PLAN OF MERGER by and among SANGAMO BIOSCIENCES, INC. CGACQUISITION SUB, INC. and CEREGENE, INC. and HAMILTON BIOVENTURESERVICES, INC., as Stockholders Representative... (Filed With SEC on October 7, 2013)

6,100,000 Shares of Common Stock par value $0.001 915,000 Over-Allotment Shares Sangamo BioSciences, Inc. UNDERWRITING AGREEMENT (Filed With SEC on September 18, 2013)

SANGAMO BIOSCIENCES, INC. RESTRICTED STOCK UNIT ISSUANCE AGREEMENT (Filed With SEC on June 14, 2013)

SANGAMO BIOSCIENCES, INC. NOTICE OF GRANT OF STOCK OPTION (Filed With SEC on June 14, 2013)

SANGAMO BIOSCIENCES, INC. STOCK OPTION AGREEMENT (Filed With SEC on June 14, 2013)

SANGAMO BIOSCIENCES, INC. NOTICE OF GRANT OF NON-EMPLOYEE DIRECTOR AUTOMATIC STOCK OPTION (Filed With SEC on June 14, 2013)

SANGAMO BIOSCIENCES, INC. AUTOMATIC STOCK OPTION AGREEMENT (Filed With SEC on June 14, 2013)

FIFTH AMENDMENT TO THE LICENSE AGREEMENT (Filed With SEC on May 9, 2013)

FOURTH AMENDMENT TO THE LICENSE AGREEMENT (Filed With SEC on November 2, 2012)

SANGAMO BIOSCIENCES, INC. INCENTIVE COMPENSATION PLAN ARTICLE I NAME AND PURPOSE (Filed With SEC on June 27, 2012)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on February 23, 2012)

COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on February 23, 2012)

*** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION (Filed With SEC on August 5, 2011)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on August 5, 2011)

EMPLOYMENT AGREEMENT (Filed With SEC on August 5, 2011)

6,700,000 Shares Sangamo BioSciences, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 11, 2011)

SEVENTH AMENDMENT OF THE RESEARCH AND COMMERCIAL LICENSE OPTION AGREEMENT (Filed With SEC on February 17, 2011)

FIRST AMENDMENT OF THE LICENSE AGREEMENT (Filed With SEC on November 6, 2009)

SECOND AMENDMENT OF THE LICENSE AGREEMENT (Filed With SEC on November 6, 2009)

THIRD AMENDMENT TO THE LICENSE AGREEMENT (Filed With SEC on November 6, 2009)

3,000,000 Shares Sangamo Biosciences, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on October 13, 2009)

COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on October 5, 2009)

LICENSE AGREEMENT (Filed With SEC on March 3, 2009)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on March 3, 2009)

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on March 3, 2009)

RESEARCH AND LICENSE AGREEMENT (Filed With SEC on November 4, 2008)

*** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION 2. (Filed With SEC on November 4, 2008)

LICENSE AGREEMENT (Filed With SEC on August 7, 2008)

AMENDMENT TO 2004 STOCK INCENTIVE PLAN (Filed With SEC on August 7, 2008)

SECOND RESEARCH AND LICENSE AGREEMENT BETWEEN GENENTECH, INC. (Filed With SEC on May 9, 2008)

*** CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION (Filed With SEC on May 9, 2008)

SANGAMO BIOSCIENCES, INC. (Filed With SEC on December 3, 2007)

our strategy (Filed With SEC on November 1, 2007)

Current assets (Filed With SEC on August 9, 2007)

Placement Agency Agreement dated July 16, 2007 between Sangamo BioSciences, Inc. and JMP Securities, Piper Jaffray & Co., Leerink Swann & Company and Janney Montgomery Scott LLC (Filed With SEC on July 17, 2007)

COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on July 10, 2007)

SANGAMO BIOSCIENCES, INC. 3,000,000 SHARES (Filed With SEC on May 18, 2007)

our strategy (Filed With SEC on March 1, 2007)

Asset Purchase Agreement (Filed With SEC on December 28, 2006)

3,100,000 Shares SANGAMO BIOSCIENCES, INC. Common Stock PURCHASE AGREEMENT (Filed With SEC on June 16, 2006)

our strategy (Filed With SEC on March 16, 2006)

/s/ Dr. Casey Case Dr. Casey Case November 18, 2005 Date (Filed With SEC on November 22, 2005)

TERMINATION OF SUBSCRIPTION AGREEMENT (Filed With SEC on November 18, 2005)

5,080,000 Shares SANGAMO BIOSCIENCES, INC. Common Stock PLACEMENT AGENCY AGREEMENT (Filed With SEC on November 14, 2005)

SUBSCRIPTION AGREEMENT (Filed With SEC on November 14, 2005)

our strategy (Filed With SEC on February 23, 2005)

THIRDAMENDMENT TO LICENSEAGREEMENT (Filed With SEC on February 24, 2004)

SECOND AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on March 27, 2003)

FIRST AMENDMENT TO RESEARCH FUNDING AGREEMENT (Filed With SEC on March 27, 2003)

Category

Industry

Companies

Contracts

SANGAMO THERAPEUTICS, INC Contracts & Agreements